首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >Characterization of immune responses in gastric cancer patients: a possible impact of H. pylori to polarize a tumor-specific type 1 response?
【24h】

Characterization of immune responses in gastric cancer patients: a possible impact of H. pylori to polarize a tumor-specific type 1 response?

机译:胃癌患者免疫应答的特征:幽门螺杆菌极化肿瘤特异性1型应答的可能影响?

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Recently, we were able to show that Helicobacter pylori-positive gastric cancer (GC) patients have a significantly better survival after the complete resection of their tumor compared to H. pylori-negative GC patients. H. pylori is known to polarize an immune response towards a type 1 cytokine profile and tumor-specific type 1 cytokine responses are associated with protection from tumor challenge and T-cell-mediated tumor regression. Therefore, we hypothesized that the improved survival in H. pylori-positive patients may be secondary to the induction of a GC-specific type 1 T cell response. To characterize the anti-tumor immune response in GC patients we analyzed tumor-infiltrating lymphocytes (TIL) isolated from primary tumors. The CD3+ T cell population contained 50% CD4+ (range 0.4-81%) and 39% CD8+ cells (range 22-53%). The number of B cells (CD19+, P = 0.03) was significantly increased and the number of T cells (CD3+, P = 0.02) significantly decreased in intestinal compared to diffuse type of tumors. Four tumor cell lines were established from primary GCs and three from lymph node metastases. T cell cultures were established from isolated TIL from four H. pylori-positive and one H. pylori-negative GC patients and tested for tumor-specific cytokine secretion. Eight of ten T cell cultures derived from H. pylori-positive patients secreted both IFN-gamma and IL-5 after restimulation with autologous tumor cells. The only tumor-specific TIL line expressing a dominant IL-5 response was derived from an H. pylori-negative patient.
机译:最近,我们能够证明幽门螺杆菌阳性胃癌(GC)患者与幽门螺杆菌阴性GC患者相比,在完全切除肿瘤后生存率明显提高。幽门螺杆菌已知会极化针对1型细胞因子分布的免疫反应,而肿瘤特异性1型细胞因子反应与保护免受肿瘤攻击和T细胞介导的肿瘤消退有关。因此,我们假设幽门螺杆菌阳性患者的生存改善可能是诱导GC特异性1型T细胞反应的继发因素。为了表征GC患者的抗肿瘤免疫反应,我们分析了从原发性肿瘤中分离的肿瘤浸润淋巴细胞(TIL)。 CD3 + T细胞群包含50%的CD4 +(范围为0.4-81%)和39%的CD8 +细胞(范围为22-53%)。与弥散型肿瘤相比,肠道中的B细胞数量(CD19 +,P = 0.03)显着增加,而T细胞数量(CD3 +,P = 0.02)显着减少。从原发性GC建立了四个肿瘤细胞系,从淋巴结转移建立了三个。从四名幽门螺杆菌阳性和一名幽门螺杆菌阴性GC患者的分离的TIL中建立T细胞培养物,并测试其肿瘤特异性细胞因子的分泌。源自幽门螺杆菌阳性患者的十个T细胞培养物中的八个在用自体肿瘤细胞再刺激后分泌IFN-γ和IL-5。唯一表达显性IL-5反应的肿瘤特异性TIL系来自幽门螺杆菌阴性患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号